Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials | Journal for ImmunoTherapy of Cancer | Full Text
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
How to Improve Survey Response Rates?
Pathologic Complete Response as a Surrogate Endpoint in Breast Cancer - touchONCOLOGY
ASH 2020: Results From the Phase 1/2 BRUIN Trial
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy - ScienceDirect
Best tumor response and overall response rate (ORR) by disease site (n... | Download Table
For personal use only
Characterization of a Real-World Response Variable and Comparison with RECIST-Based Response Rates from Clinical Trials in Advanced NSCLC | SpringerLink
I never lost hope” – One Man's Journey with Advanced Kidney Cancer
A nomogram based on clinicopathological features and serological indicators predicting breast pathologic complete response of neoadjuvant chemotherapy in breast cancer | Scientific Reports
Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial | PLOS ONE
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma | NEJM
Response rates Overall response rate and depth of response according to... | Download Scientific Diagram
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Objective response rate assessment in oncology: Current situation and future expectations
Investigator-assessed confirmed objective response rate (per RECIST),... | Download Scientific Diagram
IKCS 2022: Real-world Clinical Outcomes of Patients with Metastatic Renal Cell Carcinoma Receiving Pembrolizumab + Axitinib vs Ipilimumab + Nivolumab
The overall response rate | Download Table
Objective response rate (A) and complete response rate (B) for the four... | Download Scientific Diagram
